Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
June 30 2023 - 8:25AM
Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage
pharmaceutical company focused on the development and
commercialization of therapies for patients with rare, genetic,
mitochondrial diseases, today announced that the company’s
management team will participate at the SVB Securities Therapeutics
Forum.
SVB Securities Therapeutics ForumDate: Tuesday,
July 11th – Wednesday, July 12th, 2023Location: The Lotte Palace,
New York, N.Y.
About Reneo PharmaceuticalsReneo is a
clinical-stage pharmaceutical company focused on the development
and commercialization of therapies for patients with rare genetic
mitochondrial diseases, which are often associated with the
inability of mitochondria to produce adenosine triphosphate (ATP).
Our lead product candidate, mavodelpar (REN001), is a potent and
selective agonist of the peroxisome proliferator-activated receptor
delta (PPARδ). Mavodelpar has been shown to increase transcription
of genes involved in mitochondrial function, increase fatty acid
oxidation, and may increase production of new mitochondria. For
additional information, please see reneopharma.com.
Contacts:
Danielle Spangler Investor Relations Reneo
Pharmaceuticals, Inc. dspangler@reneopharma.com
Matthew Purcell, Pharm.D.Media Inquiries Russo Partners,
LLC matthew.purcell@russopartnersllc.com
Reneo Pharmaceuticals (NASDAQ:RPHM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Reneo Pharmaceuticals (NASDAQ:RPHM)
Historical Stock Chart
From Jul 2023 to Jul 2024